Published human case reports on self-administered fenbendazole reveal two main outcomes: significant tumor regression/remissions in several cancer types and reversible drug-induced hepatotoxicity.
1. Documented Antitumor Responses & Tumor Regressions
Diffuse Large B-Cell Lymphoma (DLBCL): An 83-year-old male with Stage IVa DLBCL who declined standard chemotherapy self-administered oral fenbendazole. Serial PET/CT scans over 12 months showed progressive improvement in lymphadenopathy and regression of hypermetabolic lesions with no new disease sites.
Metastatic Renal Cell Carcinoma (mRCC): A 63-year-old male with clear cell RCC who had intolerable side effects or disease progression on multiple therapies (pazopanib, cabozantinib, nivolumab) initiated fenbendazole. Interval MRI showed near-complete resolution of the primary renal mass and reduced pancreatic and bone lesions, with no new lesions over 10 months.
High-Grade Urothelial Carcinoma (HGUC): A 72-year-old male with progressive retroperitoneal nodal disease while on pembrolizumab maintenance added fenbendazole alongside vitamin E, curcumin, and CBD oil. Serial CT scans over 9 months showed decreased tumor size, achieving a complete radiographic response.
Urothelial Bladder Carcinoma: A 63-year-old female received fenbendazole concurrently with AMVAC chemotherapy, achieving no evidence of disease on follow-up CT with minimal residual thickening.
Small-Cell Lung Cancer (Anecdotal): The widely cited case of Joe Tippens involved self-administering fenbendazole (222 mg/day) alongside vitamin E, CBD oil, and curcumin during an experimental trial, resulting in complete clearance of detectable cancer cells on a PET scan at 3 months.
2. Common Self-Administered Dosing Regimen
In most published case reports, patients followed a self-directed schedule of 1 gram of oral fenbendazole once daily for 3 consecutive days, followed by 4 days off per week. In the DLBCL case, higher initial daily dosing (up to 1 g/day continuously) led to peripheral neuropathy, requiring a dose reduction and gradual tapering down to 3 tablets per week.
3. Hepatotoxicity & Safety Concerns
Severe Drug-Induced Liver Injury (DILI): A 67-year-old female self-administering fenbendazole for one year developed severe DILI confirmed by liver biopsy (RUCAM score 9). Discontinuing fenbendazole led to rapid recovery of liver function.
Combined Immunotherapy/Fenbendazole Hepatotoxicity: An 80-year-old female with metastatic non-small-cell lung cancer taking pembrolizumab developed severe hepatic dysfunction after one month of fenbendazole self-administration. Liver function normalized rapidly after she discontinued fenbendazole, though she showed no antitumor response in her lung lesions.
4. Overall Clinical Evaluation
While case reports document notable tumor regressions, researchers emphasize that these reports are observational or anecdotal. Due to the risk of reversible liver toxicity and lack of standardized clinical trial data, formal prospective clinical trials are necessary to confirm safety, establish human therapeutic dosing, and identify potential drug interactions.
Fenbendazole Regimens
Based on published case reports and literature reviews, the self-administered dosing schedules for fenbendazole generally fall into a few common patterns:
1. The Standard “3 Days On, 4 Days Off” Regimen
Dose & Schedule: The most widely reported regimen in patient case studies involves taking 1 gram (1,000 mg) of oral fenbendazole once daily for 3 consecutive days, followed by 4 days off treatment each week.
Rationale: This pulsed schedule is frequently adopted from online patient communities and anecdotal self-care reports to manage potential drug accumulation and reduce systemic toxicity.
2. The “Joe Tippens” Protocol
Dose & Schedule: Popularized after the widely cited case of Joe Tippens, this regimen uses 222 mg of oral fenbendazole daily.
Concomitant Supplements: The protocol is typically taken as part of a multi-agent regimen that includes:
Vitamin E
CBD oil
Bioavailable curcumin
3. Continuous High-Dose Schedules & Tapering
Initial High Dose: Some patients start with a continuous daily dose of 1 gram (or fluctuating between 1 and 6 tablets daily).
Tapering for Toxicity: Continuous high-dose regimens have been associated with side effects such as peripheral neuropathy or drug-induced liver injury (DILI). In response to side effects, patients in case reports often reduced their intake to 1–3 tablets daily or tapered down to a maintenance schedule of 3 tablets per week.
4. Food & Bioavailability Considerations
Fatty Meals / Food: Because fenbendazole has very poor water solubility and low intestinal absorption, self-administration guides and reports often recommend taking the medication with food, especially fatty meals, to improve gastrointestinal absorption and systemic availability.
Reference
Nguyen, J., Nguyen, T. Q., Han, B., & Hoang, B. X. (2024). Oral fenbendazole for cancer therapy in humans and animals. Anticancer Research, 44(9), 3725–3735.